Javier Calleja-Conde1, Victor Echeverry-Alzate1, Elena Giné2, Kora-Mareen Bühler1, Roser Nadal3, Rafael Maldonado4, Fernando Rodríguez de Fonseca1,5, Antoni Gual6, Jose Antonio López-Moreno1. 1. Department of Psychobiology, School of Psychology, Campus de Somosaguas, Complutense University of Madrid, Madrid, Spain. 2. Department of Cellular Biology, School of Medicine, Complutense University of Madrid, Madrid, Spain. 3. Psychobiology Unit, School of Psychology, Institut de Neurociències, Universitat Autònoma de Barcelona, Barcelona, Spain. 4. Laboratori de Neurofarmacologia, Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain. 5. Instituto IBIMA de Málaga, Unidad de Gestión Clínica de Salud Mental, Hospital Regional Universitario, Málaga, Spain. 6. Addictions Unit, Department of Psychiatry, Clinical Institute of Neuroscience, Hospital Clínic, Barcelona, Spain.
Abstract
BACKGROUND AND PURPOSE: The opioid antagonist nalmefene (selincro®) was approved for alcohol-related disorders by the European Medicines Agency in 2013. However, there have been no studies regarding the effectiveness of nalmefene when alcohol is used in combination with cocaine. EXPERIMENTAL APPROACH: Using operant alcohol self-administration in Wistar rats and qRT-PCR, we evaluated (i) the dose-response curve for s.c. and p.o. nalmefene; (ii) the effects of nalmefene with increasing concentrations of alcohol; (iii) the efficacy of nalmefene on cocaine-potentiated alcohol responding; and (iv) the gene expression profiles of histone deacetylases (Hdac1-11) in peripheral blood in vivo and in the prefrontal cortex, heart, liver and kidney post mortem. KEY RESULTS: S.c. (0.01, 0.05, 0.1 mg·kg(-1) ) and p.o. (10, 20, 40 mg·kg(-1) ) nalmefene dose-dependently reduced alcohol-reinforced responding by up to 50.3%. This effect of nalmefene was not dependent on alcohol concentration (10, 15, 20%). Cocaine potentiated alcohol responding by approximately 40% and nalmefene (0.05 mg·kg(-1) ) reversed this effect of cocaine. Alcohol increased Hdac gene expression in blood and nalmefene prevented the increases in Hdacs 3, 8, 5, 7, 9, 6 and 10. In the other tissues, alcohol and nalmefene either did not alter the gene expression of Hdacs, as in the prefrontal cortex, or a tissue-Hdac-specific effect was observed. CONCLUSIONS AND IMPLICATIONS: Nalmefene might be effective as a treatment for alcohol-dependent patients who also use cocaine. Also, the expression of Hdacs in peripheral blood might be useful as a biomarker of alcohol use and drug response.
BACKGROUND AND PURPOSE: The opioid antagonist nalmefene (selincro®) was approved for alcohol-related disorders by the European Medicines Agency in 2013. However, there have been no studies regarding the effectiveness of nalmefene when alcohol is used in combination with cocaine. EXPERIMENTAL APPROACH: Using operant alcohol self-administration in Wistar rats and qRT-PCR, we evaluated (i) the dose-response curve for s.c. and p.o. nalmefene; (ii) the effects of nalmefene with increasing concentrations of alcohol; (iii) the efficacy of nalmefene on cocaine-potentiated alcohol responding; and (iv) the gene expression profiles of histone deacetylases (Hdac1-11) in peripheral blood in vivo and in the prefrontal cortex, heart, liver and kidney post mortem. KEY RESULTS: S.c. (0.01, 0.05, 0.1 mg·kg(-1) ) and p.o. (10, 20, 40 mg·kg(-1) ) nalmefene dose-dependently reduced alcohol-reinforced responding by up to 50.3%. This effect of nalmefene was not dependent on alcohol concentration (10, 15, 20%). Cocaine potentiated alcohol responding by approximately 40% and nalmefene (0.05 mg·kg(-1) ) reversed this effect of cocaine. Alcohol increased Hdac gene expression in blood and nalmefene prevented the increases in Hdacs 3, 8, 5, 7, 9, 6 and 10. In the other tissues, alcohol and nalmefene either did not alter the gene expression of Hdacs, as in the prefrontal cortex, or a tissue-Hdac-specific effect was observed. CONCLUSIONS AND IMPLICATIONS: Nalmefene might be effective as a treatment for alcohol-dependent patients who also use cocaine. Also, the expression of Hdacs in peripheral blood might be useful as a biomarker of alcohol use and drug response.
Authors: Joshua D Lee; Ellie Grossman; Laura Huben; Marc Manseau; Jennifer McNeely; John Rotrosen; David Stevens; Marc N Gourevitch Journal: J Subst Abuse Treat Date: 2012-09-15
Authors: Stephen Ph Alexander; Doriano Fabbro; Eamonn Kelly; Neil Marrion; John A Peters; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2015-12 Impact factor: 8.739
Authors: Kimmo Ingman; Nora Hagelberg; Sargo Aalto; Kjell Någren; Auni Juhakoski; Sakari Karhuvaara; Antero Kallio; Vesa Oikonen; Jarmo Hietala; Harry Scheinin Journal: Neuropsychopharmacology Date: 2005-12 Impact factor: 7.853
Authors: Albert J Arias; Stephen Armeli; Joel Gelernter; Jonathan Covault; Antero Kallio; Sakari Karhuvaara; Tiina Koivisto; Rauno Mäkelä; Henry R Kranzler Journal: Alcohol Clin Exp Res Date: 2008-07 Impact factor: 3.455
Authors: Jose Antonio López-Moreno; Miguel Marcos; Javier Calleja-Conde; Victor Echeverry-Alzate; Kora M Bühler; Pilar Costa-Alba; Edgar Bernardo; Francisco-Javier Laso; Fernando Rodríguez de Fonseca; Roser Nadal; Maria Paz Viveros; Rafael Maldonado; Elena Giné Journal: Alcohol Clin Exp Res Date: 2015-09-13 Impact factor: 3.455
Authors: George F Koob; Amanda J Roberts; Brigitte L Kieffer; Charles J Heyser; Simon N Katner; Roberto Ciccocioppo; Friedbert Weiss Journal: Recent Dev Alcohol Date: 2003
Authors: V Echeverry-Alzate; K M Bühler; J Calleja-Conde; E Huertas; R Maldonado; F Rodríguez de Fonseca; C Santiago; F Gómez-Gallego; A Santos; E Giné; J A López-Moreno Journal: Psychopharmacology (Berl) Date: 2018-11-23 Impact factor: 4.530
Authors: Elizabeth M Burnette; Steven J Nieto; Erica N Grodin; Lindsay R Meredith; Brian Hurley; Karen Miotto; Artha J Gillis; Lara A Ray Journal: Drugs Date: 2022-02-08 Impact factor: 9.546